HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 2005-0487v1 24/5/1280    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shan, X. Articles by Liu, R. Search for Related Content PubMed PubMed Citation Articles by Shan, X. Articles by Liu, R.

TISSUE-SPECIFIC STEM CELLS

Enhanced De Novo Neurogenesis and Dopaminergic Neurogenesis in the Substantia Nigra of 1-Methyl-4-phyenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson’s Disease-Like Mice

Department of Anatomy and Cell Biology, University of North Dakota School of Medicine, Grand Forks, North Dakota, USA

Key Words. Parkinson’s disease • 1-Methyl-4-phyenyl-1,2,3,6-tetrahydropyridine • Dopaminergic cells • Substantia nigra • Neural progenitor cells • De novo neurogenesis

Correspondence: Rugao Liu, Ph.D., Department of Anatomy and Cell Biology, University of North Dakota School of Medicine, Grand Forks, North Dakota 58202, USA. Telephone: 701-777-2559; Fax: 701-777-2477; e-mail: rliu{at}medicine.nodak.edu

Received on October 2, 2005; accepted for publication on January 7, 2006.

Research reports on de novo neurogenesis, particularly dopaminergic (DA) neurogenesis in the adult mammalian substantia nigra (SN), remain very controversial. For this reason, we used the nestin second intron enhancer-controlled LacZ reporter transgenic mouse model coupled with the 1-methyl-4-phyenyl-1,2,3,6-tetrahydropyridine (MPTP) lesion system to investigate whether there are neurogenesis and DA neurogenesis in the SN of the adult normal and Parkinson’s disease (PD)-like mice. First, we demonstrated the presence of neural progenitor cells (NPCs), basal levels of neurogenesis, and DA neurogenesis in the normal adult mouse SN. Second, we showed that there is not only a significant increase in the number of NPCs but also a dramatic increase of neurogenesis from the NPCs in the SN and the midline region adjacent to the SN of the PD-like mice compared with that of normal controls. More importantly, we also demonstrated that there is an increase of DA neurogenesis in the SN of the MPTP-lesioned mice. Third, we showed that the increased DA neurogenesis in the MPTP-lesioned mice was derived from the NPCs and 5-bromodeoxyuridine-positive cells, suggesting that multiple stem cell lineages may contribute to the enhanced neurogenesis in the adult SN. Taken together, these results establish that there are basal levels, albeit low, and increased levels of de novo neurogenesis and DA neurogenesis in the SN of the adult normal and PD-like mice, respectively. The increased NPCs in the MPTP-lesioned mice further suggest that experimental approaches to promote de novo neurogenesis may provide an effective therapy for PD by functional replacement of degenerated DA neurons.

This article has been cited by other articles:

				B. Winner, D. M. Vogt-Weisenhorn, C. D. Lie, I. Blumcke, and J. Winkler Review: Cellular repair strategies in Parkinson's disease Therapeutic Advances in Neurological Disorders, January 1, 2009; 2(1): 51 - 60. [Abstract] [PDF]

				A. Hermann and A. Storch Endogenous Regeneration in Parkinson's Disease: Do We Need Orthotopic Dopaminergic Neurogenesis? Stem Cells, November 1, 2008; 26(11): 2749 - 2752. [Full Text] [PDF]

				M. Geraerts, O. Krylyshkina, Z. Debyser, and V. Baekelandt Concise Review: Therapeutic Strategies for Parkinson Disease Based on the Modulation of Adult Neurogenesis Stem Cells, February 1, 2007; 25(2): 263 - 270. [Abstract] [Full Text] [PDF]

				M. Timmer, K. Cesnulevicius, C. Winkler, J. Kolb, E. Lipokatic-Takacs, J. Jungnickel, and C. Grothe Fibroblast Growth Factor (FGF)-2 and FGF Receptor 3 Are Required for the Development of the Substantia Nigra, and FGF-2 Plays a Crucial Role for the Rescue of Dopaminergic Neurons after 6-Hydroxydopamine Lesion J. Neurosci., January 17, 2007; 27(3): 459 - 471. [Abstract] [Full Text] [PDF]

				J. M. Van Kampen and C. B. Eckman Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior. J. Neurosci., July 5, 2006; 26(27): 7272 - 7280. [Abstract] [Full Text] [PDF]